Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect (Q38292772)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

author name string

Chris D Nicholls

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Kevin G McLure

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Michael A Shields

3

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Patrick W K Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

language of work or name

0 references

publication date

22 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

277

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

12937-12945

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 and the Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Definition of a consensus binding site for p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

How p53 binds DNA as a tetramer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutation and cancer: statistical study of retinoblastoma

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutations in the p53 gene occur in diverse human tumour types

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mechanisms of p53 loss in human sarcomas

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 mutants without a functional tetramerisation domain are not oncogenic

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

In vitro analysis of the dominant negative effect of p53 mutants

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Solution structure of the tetrameric minimum transforming domain of p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 DNA binding can be modulated by factors that alter the conformational equilibrium

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Form of human p53 protein during nuclear transport in Xenopus laevis embryos

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

High-resolution structure of the oligomerization domain of p53 by multidimensional NMR

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Refined solution structure of the oligomerization domain of the tumour suppressor p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

The MDM2 RING-finger domain is required to promote p53 nuclear export

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

SUMO-1 modification activates the transcriptional response of p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

WAF1, a potential mediator of p53 tumor suppression

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

14-3-3sigma is a p53-regulated inhibitor of G2/M progression

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Induction of the growth inhibitor IGF-binding protein 3 by p53

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A functional p53-responsive intronic promoter is contained within the humanmdm2gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M108815200

21 January 2018

Identifiers

10.1074/JBC.M108815200

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38292772&oldid=1752364847"